Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

NCT02430909 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

159

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: Bimekizumab
BIOLOGICAL: Certolizumab Pegol
OTHER: Placebo

Sponsor

UCB Celltech

Collaborators

[object Object]